HC Wainwright Rates argenx (ARGX) buy, $940 Price Target
HC Wainwright maintains its buy rating on argenx SE, setting a $940 price target, a 5.95% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
HC Wainwright rated argenx SE ($ARGX) "buy" with a $940 price target on June 25, 2026.
Since the rating, $ARGX is up 5.7% after 1 week, up 0.0% after 1 month and down 7.8% to date (from the $888.65 close on Jun 25, 2026).
ARGX
argenx SE
Key Points
- HC Wainwright reiterated its buy rating on argenx SE, targeting a price of $940.
- HC Wainwright's $940 price target implies 5.95% upside from argenx SE's ($ARGX) current $887.18 share price.
- Shares of argenx SE traded at $852.5 on Thursday, with a market cap of approximately $56.5 billion.
- FMR LLC and Artisan Partners adjusted their positions in argenx SE, with FMR LLC reducing by 601,285 shares.
Get $ARGX trade alerts by text
We text you when insiders, Congress or big funds trade $ARGX. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated argenx SE alert may contain errors. Disclosures
HC Wainwright has reiterated its buy rating on argenx SE (NasdaqGS: ARGX), maintaining a target price of $940. Analyst Douglas Tsao confirmed the rating on June 25, 2026. The stock was trading around $852.5 on Thursday.
HC Wainwright & Co. vs. the S&P 500
Hypothetical returns from HC Wainwright & Co.'s disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in argenx SE
Several institutional investors have adjusted their holdings in argenx SE. FMR LLC reduced its stake by 601,285 shares, leaving it with 4,991,034 shares valued at approximately $3.64 billion, a 10.8% decrease. PRICE T ROWE ASSOCIATES INC /MD/ slightly increased its position by 12,631 shares, now holding 3,374,955 shares worth about $2.46 billion, a 0.4% increase. JANUS HENDERSON GROUP PLC expanded its stake by 83,568 shares, resulting in a total of 2,541,732 shares valued at $1.85 billion, a 3.4% increase. CAPITAL WORLD INVESTORS added 339,982 shares, growing its position by 17.7% to 2,256,216 shares, valued at $1.65 billion. Meanwhile, ARTISAN PARTNERS LIMITED PARTNERSHIP cut its holding by 288,960 shares, down 16.4% to 1,467,982 shares, valued at $1.07 billion.
argenx SE Stock Down 10.4%
On Thursday, shares of argenx SE (NasdaqGS: ARGX) traded near $852.5. The company has a market capitalization of about $56.5 billion and a P/E ratio of 40.2. Its forward P/E stands at 24.7, and it has a beta of -0.033, indicating low volatility compared to the market. Over the past 52 weeks, the stock has ranged from $510.06 to $934.62. The 50-day moving average is $822.67, and the 200-day moving average is $811.28.
$ARGX price target
argenx SE daily closes and this analyst's $940 target. Not advice.
Recent Earnings
argenx SE reported revenues of approximately $4.74 billion with a growth rate of 62.6%. The company achieved a net margin of 31.4%. Its earnings per share (EPS) stood at $22.47. The next earnings release is scheduled for July 23, 2026.
Analysts Set New Price Targets
On June 25, 2026, HC Wainwright & Co. reiterated its buy rating with a $940 price target. Morgan Stanley maintained its buy rating on June 24, 2026, with a target of $1,180. Wells Fargo, on June 1, 2026, maintained its buy rating with a $1,291 target. The consensus among analysts is a strong buy, with an average target price of $1,018.14 based on 22 analyst opinions.
About argenx SE
argenx SE is a biotechnology company based in Amsterdam, Netherlands. It specializes in developing therapies for autoimmune diseases. The company offers treatments like VYVGART for generalized myasthenia gravis (gMG) and immune thrombocytopenia (ITP), and VYVGART HYTRULO for gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). argenx is also working on a range of other treatments, including efgartigimod for various autoimmune conditions. The company was founded in 2008 and is led by CEO Ms. Karen Massey.
Bottom Line
HC Wainwright's reiterated buy rating for argenx SE highlights continued optimism for the company's prospects. Investors follow analyst ratings closely for insight into potential stock performance. As a reminder, analyst ratings are based on past data and don't guarantee future results.
Related Filing Alerts
Source: HC Wainwright's rating change on $ARGX (Jun 25, 2026). Written by software, not financial advice. How we make alerts